The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The outbreak of SARS-CoV-2, the cause of COVID-19, is ongoing. New and effective antiviral agents that combat the disease are needed urgently. Here, we found that an inhaled corticosteroid, ciclesonide, suppresses the replication of coronaviruses, including betacoronaviruses (murine hepatitis virus type 2 [MHV-2], MERS-CoV, SARS-CoV, and SARS-CoV-2) and an alphacoronavirus (human coronavirus 229E [HCoV-229E]), in cultured cells. Ciclesonide is safe; indeed, it can be administered to infants at high concentrations. Thus, ciclesonide is expected to be a broad-spectrum antiviral drug that is effective against many members of the coronavirus family. It could be prescribed for the treatment of MERS and COVID-19.
Article activity feed
-
SciScore for 10.1101/2020.08.22.258459: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The cells were then incubated with a mixture of rabbit anti-SARS-nsp4 (1:500; ab181620; Abcam, USA) and mouse anti-dsRNA (1:1000; J2-1709; Scicons, Hungary) antibodies for 1 h at RT, washed three times with PBS, and incubated for 1 h at RT with a mixture of Alexa Fluor 594 conjugated anti-rabbit IgG (1:500; A11012; ThermoFisher, USA) and Alexa Fluor 488-conjugated anti-mouse IgG (1:500; A10680; ThermoFisher, USA). anti-SARS-nsp4suggested: Noneanti-dsRNAsugg…SciScore for 10.1101/2020.08.22.258459: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The cells were then incubated with a mixture of rabbit anti-SARS-nsp4 (1:500; ab181620; Abcam, USA) and mouse anti-dsRNA (1:1000; J2-1709; Scicons, Hungary) antibodies for 1 h at RT, washed three times with PBS, and incubated for 1 h at RT with a mixture of Alexa Fluor 594 conjugated anti-rabbit IgG (1:500; A11012; ThermoFisher, USA) and Alexa Fluor 488-conjugated anti-mouse IgG (1:500; A10680; ThermoFisher, USA). anti-SARS-nsp4suggested: Noneanti-dsRNAsuggested: (Millipore Cat# MABE1134, RRID:AB_2819101)anti-rabbit IgGsuggested: (Molecular Probes Cat# A-11012, RRID:AB_141359)anti-mouse IgGsuggested: (Thermo Fisher Scientific Cat# A-10680, RRID:AB_2534062)Experimental Models: Cell Lines Sentences Resources Cells and viruses: Hep-2, HeLa229, MDCK, Calu-3, Vero, Vero/TMPRSS2 and VeroE6/TMPRSS2 cells were maintained in Dulbecco’s modified Eagle medium high glucose (DMEM, Sigma-Aldrich, USA), and DBT cells were maintained in DMEM (Nissui, Japan), supplemented with 5% fetal bovine serum (Gibco-BRL, USA). Hep-2suggested: NoneMDCKsuggested: CLS Cat# 602280/p823_MDCK_(NBL-2, RRID:CVCL_0422)Verosuggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)VeroE6/TMPRSS2suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)BHK-21 cells were grown in a single well of a six-well plate in 10% FCS-MEM and transfected with 3 μg of BAC plasmid with Lipofectamine 3,000 (Thermo Fisher, USA) BHK-21suggested: NoneThe supernatants were collected and propagated once using Vero/TMPRSS2 cells. Vero/TMPRSS2suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)Vero and VeroE6/TMPSS2 cells were used to passage MERS-CoV and SARS-CoV-2, respectively. VeroE6/TMPSS2suggested: NoneSoftware and Algorithms Sentences Resources Indexed libraries were then converted and sequenced (150-bp paired-end reads) using the DNBSEQ-G400 (MGI Tech., Shenzhen, China; operated by GENEWIZ, South Plainfield, NJ, USA). GENEWIZsuggested: (GENEWIZ, RRID:SCR_003177)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-